| 1 | Molecular mechanism for the activation of the anti-tuberculosis drug isoniazid by Mn(III): First detection and unequivocal identification of the critical N-centered isoniazidyl radical and its exact location. (Qin L, Huang CH, Xu D, Xie LN, Shao J, Mao L, Kalyanaraman B, Zhu BZ) Free Radic Biol Med 2019 Nov 01;143:232-239 12 Citations |
| 1 | Patient attitudes towards community-based tuberculosis DOT and adherence to treatment in an urban setting; Kampala, Uganda. (Hassard S, Ronald A, Angella K) Pan Afr Med J 2017;27:1 16 Citations |
| 1 | In vitro and in vivo fitness costs associated with Mycobacterium tuberculosis RpoB mutation H526D. (Rifat D, Campodónico VL, Tao J, Miller JA, Alp A, Yao Y, Karakousis PC) Future Microbiol 2017 Jul;12(9):753-765 22 Citations |
| 2 | Disseminated Mycotic Aneurysms following Intravesical Bacillus Calmette-Guérin Therapy for Bladder Cancer: Case Discussion and Systematic Treatment Algorithm. (Lee CJ, Davila D, Dua A, Keyashian B, Dux J, Seabrook GR, Brown K, Malinowski M, Hieb RA, Lewis B) Ann Vasc Surg 2017 Feb;39:284.e5-284.e10 7 Citations |
| 1 | Recently disclosed chemical entities as potential candidates for management of tuberculosis. (Stec J, Abourashed EA) Pharm Pat Anal 2015;4(4):317-47 3 Citations |
| 1 | Mutations in the β subunit of RNA polymerase alter intrinsic cephalosporin resistance in Enterococci. (Kristich CJ, Little JL) Antimicrob Agents Chemother 2012 Apr;56(4):2022-7 29 Citations |
| 1 | Tuberculin skin test and isoniazid prophylaxis among health care workers in high tuberculosis prevalence areas. (Khawcharoenporn T, Apisarnthanarak A, Sungkanuparph S, Woeltje KF, Fraser VJ) Int J Tuberc Lung Dis 2011 Jan;15(1):14-23 13 Citations |
| 1 | A unique paradoxical reaction to tuberculosis therapy: case report and brief review of the literature. (Singh B, Iqbal FM, Sunkavalli KK, Chawla B) Am J Ther 2013;20(6):e706-9 5 Citations |
| 1 | Synthesis and bio-evaluation of alkylaminoaryl phenyl cyclopropyl methanones as antitubercular and antimalarial agents. (Ajay A, Singh V, Singh S, Pandey S, Gunjan S, Dubey D, Sinha SK, Singh BN, Chaturvedi V, Tripathi R, Ramchandran R, Tripathi RP) Bioorg Med Chem 2010 Dec 01;18(23):8289-301 31 Citations |
| 1 | In silico structure-based design of a novel class of potent and selective small peptide inhibitor of Mycobacterium tuberculosis Dihydrofolate reductase, a potential target for anti-TB drug discovery. (Kumar M, Vijayakrishnan R, Subba Rao G) Mol Divers 2010 Aug;14(3):595-604 33 Citations |
| 1 | Structure-based design of a novel class of potent inhibitors of InhA, the enoyl acyl carrier protein reductase from Mycobacterium tuberculosis: a computer modelling approach. (Subba Rao G, Vijayakrishnan R, Kumar M) Chem Biol Drug Des 2008 Nov;72(5):444-9 29 Citations |
© 2025 Clinical & Translational Science Institute